advertisement
Higashide T 26
Showing records 1 to 25 | Display all abstracts from Higashide T90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Ohshima Y
PLoS ONE 2020; 15: e0242090
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Inatani M
Advances in Therapy 2021; 38: 1116-1129
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Inatani M
Advances in Therapy 2021; 38: 1106-1115
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Higashide T
PLoS ONE 2020; 15: e0242090
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Higashide T
Advances in Therapy 2021; 38: 1106-1115
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Higashide T
Advances in Therapy 2021; 38: 1116-1129
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Sakaguchi K
PLoS ONE 2020; 15: e0242090
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Matsushita K
Advances in Therapy 2021; 38: 1116-1129
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Matsushita K; Nagasato D
Advances in Therapy 2021; 38: 1106-1115
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Miki A
Advances in Therapy 2021; 38: 1116-1129
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Sasaki M
PLoS ONE 2020; 15: e0242090
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Takagi H
Advances in Therapy 2021; 38: 1106-1115
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Ueki M
Advances in Therapy 2021; 38: 1116-1129
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Udagawa S
PLoS ONE 2020; 15: e0242090
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Ueki M
Advances in Therapy 2021; 38: 1106-1115
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Ohkubo S
PLoS ONE 2020; 15: e0242090
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Iwamoto Y; Kobayashi M
Advances in Therapy 2021; 38: 1116-1129
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Yoneda T
PLoS ONE 2020; 15: e0242090
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Takai Y
Advances in Therapy 2021; 38: 1106-1115
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Leal S
Advances in Therapy 2021; 38: 1116-1129
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Miyazaki K
Advances in Therapy 2021; 38: 1106-1115
90956 The association of primary aldosteronism with glaucoma-related fundus abnormalities
Sugiyama K
PLoS ONE 2020; 15: e0242090
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Leal S
Advances in Therapy 2021; 38: 1116-1129
91677 Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study
Iwamoto Y
Advances in Therapy 2021; 38: 1106-1115
91743 Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Advances in Therapy 2021; 38: 1116-1129
